mlsanityData to 7 Oct 2026

KGML-xDTD: A Knowledge Graph-based Machine Learning Framework for Drug Treatment Prediction and Mechanism Description

arXiv 2212.01384 ↗First posted 30 Nov 2022q-bio.QM cs.LGcited by 4

Not on the map. Why?

Abstract (arXiv)

Background: Computational drug repurposing is a cost- and time-efficient approach that aims to identify new therapeutic targets or diseases (indications) of existing drugs/compounds. It is especially critical for emerging and/or orphan diseases due to its cheaper investment and shorter research cycle compared with traditional wet-lab drug discovery approaches. However, the underlying mechanisms of action (MOAs) between repurposed drugs and their target diseases remain largely unknown, which is still a main obstacle for computational drug repurposing methods to be widely adopted in clinical settings. Results: In this work, we propose KGML-xDTD: a Knowledge Graph-based Machine Learning framework for explainably predicting Drugs Treating Diseases. It is a two-module framework that not only predicts the treatment probabilities between drugs/compounds and diseases but also biologically explains them via knowledge graph (KG) path-based, testable mechanisms of action (MOAs). We leverage knowledge-and-publication based information to extract biologically meaningful "demonstration paths" as the intermediate guidance in the Graph-based Reinforcement Learning (GRL) path-finding process. Comprehensive experiments and case study analyses show that the proposed framework can achieve state-of-the-art performance in both predictions of drug repurposing and recapitulation of human-curated drug MOA paths. Conclusions: KGML-xDTD is the first model framework that can offer KG-path explanations for drug repurposing predictions by leveraging the combination of prediction outcomes and existing biological knowledge and publications. We believe it can effectively reduce "black-box" concerns and increase prediction confidence for drug repurposing based on predicted path-based explanations, and further accelerate the process of drug discovery for emerging diseases.

Key facts. Cited by 4 papers in the map (data through 7 Oct 2026). Builds on 20 of its 107 references that are in the map. First posted on arXiv 30 Nov 2022.

Builds on

20 of 107 references.

References · 20

  1. 2014Adam: A Method for Stochastic Optimizationcited by 36,960
  2. 2017Graph Attention Networkscited by 8,854
  3. 2017Inductive Representation Learning on Large Graphscited by 6,284
  4. 2013Distributed Representations of Words and Phrases and their Compositionalitycited by 3,462
  5. 2015Continuous control with deep reinforcement learningcited by 3,279
  6. 2020Domain-Specific Language Model Pretraining for Biomedical Natural Language Processingcited by 996
  7. 2014Embedding Entities and Relations for Learning and Inference in Knowledge Basescited by 929
  8. 2016Complex Embeddings for Simple Link Predictioncited by 897
  9. 2019RotatE: Knowledge Graph Embedding by Relational Rotation in Complex Spacecited by 893
  10. 2018SimplE Embedding for Link Prediction in Knowledge Graphscited by 195
  11. 2018Multi-Hop Knowledge Graph Reasoning with Reward Shapingcited by 102
  12. 2017Analogical Inference for Multi-Relational Embeddingscited by 69
8 more
  1. 2020Network Medicine Framework for Identifying Drug Repurposing Opportunities for COVID-19cited by 38
  2. 2021A Review of Biomedical Datasets Relating to Drug Discovery: A Knowledge Graph Perspectivecited by 37
  3. 2020COVID-19 Literature Knowledge Graph Construction and Drug Repurposing Report Generationcited by 32
  4. 2018Embedding Uncertain Knowledge Graphscited by 25
  5. 2021Neural Multi-Hop Reasoning With Logical Rules on Biomedical Knowledge Graphscited by 25
  6. 2020Few-shot link prediction via graph neural networks for Covid-19 drug-repurposingcited by 21
  7. 2022Biolink Model: A Universal Schema for Knowledge Graphs in Clinical, Biomedical, and Translational Sciencecited by 13
  8. 2020Drug repurposing for COVID-19 using graph neural network and harmonizing multiple evidencecited by 10

Built on by

Cited by year (2026 to 7 Oct)

Citing papers per year: 2024: 1; 2025: 2; 2026: 1.

4 papers.